EYA2 promotes lung cancer cell proliferation by downregulating the expression of PTEN

Abstract

Lung cancer is the leading cause of cancer-related death worldwide. Despite advances have been made in diagnosis and therapeutic strategies, the prognosis of lung cancer is still very poor. Eyes absent transcriptional cofactor EYA2 has been shown to promote lung cancer cell growth, however, the underlying molecular mechanism is still not fully understood. In the present study, we found that EYA2 was up-regulated in lung cancer, and EYA2 led to increased cell proliferation by inhibiting Phosphatase and tensin homologue (PTEN) expression via modulation of miR-93. Additionally, survival analysis showed that lung cancer patients with higher EYA2 expression predicted a worse prognosis. Therefore, these findings demonstrate that EYA2 may play an important role in lung cancer occurrence and progression. Targeting EYA2 may provide a feasible approach in developing novel anticancer therapeutics.

miR-219a-5p represses migration and invasion of osteosarcoma cells via targeting EYA2

“…EYA2, function as tyrosine phosphatases or transcriptional coactivator, was reported to be an oncogene in various cancers [8,22]. However, the expression and role of EYA2 in OS remains unknown.…”

“…For example, EYA2, function as a tumour suppressor, is downregulated in pancreatic cancers tissues and cells, and epigenetic expression of EYA2 repressed the growth and metastases of pancreatic adenocarcinoma [7]. But many more studies described EYA2 as an oncogene in breast cancer, lung adenocarcinoma, astrocytoma, leukemogenesis and cervical carcinogenesis [8][9][10][11][12][13]. However, the expression and role of EYA2 in OS remain unclear.…”

EYA2 Correlates With Clinico-Pathological Features of Breast Cancer, Promotes Tumor Proliferation, and Predicts Poor Survival

“…Recently, the dysregulation of EYA2 has been reported to be involved in several human cancers (15–18). For instance, EYA2 expression was enhanced in multiple tumors in comparison with corresponding normal tissues (16, 17). EYA2 can promote tumor growth in diverse tumor types (16–19).…”

“…For instance, EYA2 expression was enhanced in multiple tumors in comparison with corresponding normal tissues (16, 17). EYA2 can promote tumor growth in diverse tumor types (16–19). In human astrocytoma, EYA2 promoted cell cycle progression of tumor cells via the up-regulation of cyclin D1 and cyclin E (17).…”

“…The association between EYA2 and clinical outcomes is controversial. High EYA2 level has been demonstrated to be a negative element for prognosis in lung cancer (16), while EYA2 predicted better clinical outcomes in colorectal cancer (15) and pancreatic cancer (21).…”